One and Done
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
On February 27, 2021, the FDA issued an emergency use authorization for a one-dose SARS-CoV-2 vaccine developed by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson.
The spike glycoprotein of SARS-CoV-2 contains a cleavage site for host cell proteases called furins. Deciphering the role of this cleavage site during infection is important for understanding the origin of the pandemic virus and its disease pattern in humans. Back in February it was not known if the furin site in the SARS-CoV-2 was …